Omeros (OMER) Gets a Hold from Needham

Needham analyst Serge Belanger maintained a Hold rating on Omeros (OMER – Research Report) today. The company’s shares closed yesterday at $3.19.

Belanger covers the Healthcare sector, focusing on stocks such as Liquidia Technologies, Esperion, and KalVista Pharmaceuticals. According to TipRanks, Belanger has an average return of 2.9% and a 43.00% success rate on recommended stocks.

The word on The Street in general, suggests a Hold analyst consensus rating for Omeros.

OMER market cap is currently $200.5M and has a P/E ratio of -1.70.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Omeros (OMER) Company Description:

Omeros Corp. operates as a biopharmaceutical company. It engages in the discovery, development, and commercializes of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.